Payrailz
Purchase-Price Allocation
Intangibles
$119.9M
2 years of history · ending 2025-06-30 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 35.00% | 35.00% | 35.00% | 35.00% | 35.00% | 35.00% |
| State & Local Income Taxes | 2.50% | 2.60% | 2.20% | 2.20% | 2.80% | 1.40% |
| Foreign Rate Differential | — | — | — | — | — | — |
| Other Adjustments | 1.00% | 0.70% | -0.20% | 0.20% | 0.30% | 0.40% |
| R&D Tax Credits | -0.70% | -2.00% | 1.80% | 3.50% | 0.80% | 1.50% |
| Qualified Production Activities (Legacy DPAD) | -3.00% | -2.50% | 2.20% | 2.30% | 2.20% | 2.00% |
| Effective Tax Rate | 34.80% | 33.80% | 33.00% | 31.60% | 35.10% | 33.30% |
Cash vs Accrual
| Item | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $62.9M | $70.0M | $75.0M | $77.5M | $100.9M | $105.2M |
| Income Taxes Paid (Cash) | — | — | — | — | — | — |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Purchase-Price Allocation
Intangibles
$119.9M
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).